top of page
  • Writer's pictureRenovion

Exploristics signs collaboration agreement with Renovion, using the cloud-based simulation platform

Exploristics is pleased to announce today a collaboration with Renovion using Exploristics’

innovative study simulation software platform KerusCloud to establish a more efficient data-driven approach to study design and protocol development within Renovion’s clinical

development programs. Implemented across two projects, KerusCloud will deliver valuable

quantitative insights to reduce the risks, costs, and duration of development programs in

non cystic fibrosis bronchiectasis (NCFBRE) and chronic obstructive pulmonary disease


Exploristics CEO Aiden Flynn said “We are delighted to be working with Renovion to harness KerusCloud’s powerful and realistic simulations to inform these important projects and ensure that their clinical trials are primed for success. With the KerusCloud software and our wraparound services, Renovion will be well-placed to exploit the unique data-driven insights that these tools can deliver to expedite the development of their ARINA-1 therapy.”

“In any clinical trial, starting with the ‘end in mind’ is the key to success,” said Dan Copeland

CEO of Renovion. “When the COPD Foundation introduced us to Exploristics, we were

immediately impressed with the team and the way in which the KerusCloud platform can be

used to model results to benefit not only this study but future studies.”

The COPD Foundation seeks to increase the number of therapies available for people with

Bronchiectasis and COPD and one way to do that is by optimizing the design and efficiency

of clinical trials and using the right endpoints. ARINA-1 clinical development plan could

benefit from collaborating with world class experts in the COPDF network. Bruce Miller,

PhD, Sr. Scientific Director COPD360Net commented “Renovion, Exploristics and the COPD

Foundation’s collaboration builds on the COPD Foundation’s global network to ensure

patient-centered, innovative and efficient clinical development of ARINA-1. This work

extends the COPD Foundation’s ongoing work with Exploristics to support our

Bronchiectasis and NTM Research Registry.”

About KerusCloud

KerusCloud is a uniquely powerful study simulation software platform that ensures clinical

studies are suitably designed statistically from the outset to maximise their chances of

success. To do this, KerusCloud creates highly realistic synthetic data sets (virtual

populations) which are then used as a basis for generating thousands of study simulations

that accurately mimic the complexity of real clinical studies. This allows researchers

evaluate the performance of a wide variety of study designs and comprehensively analyse

options in silico in minutes to efficiently choose the best options for real studies. For more

information about KerusCloud, visit

About Exploristics

Exploristics is an enabling technology company that transforms clinical development for life

science organisations with unique proprietary software and biostatistics services for

planning, designing, and analysing clinical studies. For more information about Exploristics,

visit or follow Exploristics on LinkedIn or Twitter.

About Renovion

Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, a

novel nebulized therapy delivered to the lungs to treat pulmonary diseases. ARINA-1 clears

mucus and reduces damaging inflammation in the airways to restore lung health. ARINA-1 is

poised to start clinical trials in chronic inflammatory airways diseases, including non-cystic

fibrosis (CF) bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD). The

Renovion team has in-depth experience in drug development with extensive scientific

expertise in chronic pulmonary conditions and inflammation. For more information on

Renovion, visit or follow Renovion on Twitter.

About the COPD Foundation

The COPD Foundation is a not-for-profit organization established to improve the lives of

people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease

through initiatives that expand services and speed innovations that will make treatment

more effective and affordable. The Foundation does this through scientific research,

education, advocacy, and awareness with the goal of disease prevention, slowed

progression, and ultimately a cure. The COPD Foundation’s Digital Health and Therapeutics

Accelerator Network (COPD360Net) supports the development and adoption of novel digital health tools, medical devices, and therapeutics that treat COPD, bronchiectasis, and NTM lung disease. COPD360Net consists of COPD Foundation accredited centers and practice-based research networks; experts in COPD and related lung diseases; relevant subject matter experts, including primary care physicians; clinical trial designers; health economists; and psychosocial experts.

To learn more, visit the COPD Foundation website or follow the Foundation on LinkedIn and Twitter.



bottom of page